CoChat

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. METHODS AND FINDINGS: NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid. CONCLUSIONS: The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease. TRIAL REGISTRATION: Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002660

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flowchart of the NILVAD study according to the CONSORT guideline. ADAS, Alzheimer’s Disease Assessment Scale-Cognitive Subscale 12 item; BP, blood pressure; CDR, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia; ECG, electrocardiogram; IMP, investigational medicinal product; NILVAD, Nilvadipine in Alzheimer disease; SMMSE, Standardised Mini-Mental State Examination.
Fig 1 Flowchart of the NILVAD study according to the CONSORT guideline. ADAS, Alzheimer’s Disease Assessment Scale-Cognitive Subscale 12 item; BP, blood pressure; CDR, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia; ECG, electrocardiogram; IMP, investigational medicinal product; NILVAD, Nilvadipine in Alzheimer disease; SMMSE, Standardised Mini-Mental State Examination.CC BY · PubMed Central
Fig 2 Estimated marginal means and 95% confidence intervals of the per-visit change from baseline in cognition and functional performance, as measured by the primary and key secondary outcomes, respectively. ADAS/ADAS-Cog 12, Alzheimer's Disease Assessment Scale Cognitive-12; CDR/CDR-sb, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia.
Fig 2 Estimated marginal means and 95% confidence intervals of the per-visit change from baseline in cognition and functional performance, as measured by the primary and key secondary outcomes, respectively. ADAS/ADAS-Cog 12, Alzheimer's Disease Assessment Scale Cognitive-12; CDR/CDR-sb, Clinical Dementia Rating Scale sum of boxes; DAD, Disability Assessment for Dementia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 195

Metadata

Authors
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., Breuilh, L., Daly, L., Hendrix, S., Aisen, P., Gaynor, S., Sheikhi, A., Taekema, D. G., Verhey, F. R., Nemni, R., Nobili, F., Franceschi, M., Frisoni, G., Zanetti, O., Konsta, A., Anastasios, O., Nenopoulou, S., Tsolaki-Tagaraki, F., Pakaski, M., Dereeper, O., de la Sayette, V., Sénéchal, O., Lavenu, I., Devendeville, A., Calais, G., Crawford, F., Mullan, M., & for the NILVAD Study Group
Affiliations
  • Trinity College Dublin (IE)
  • University College Dublin (IE)
  • King's College London (GB)
  • Université de Lille (FR)
  • G. Papanikolaou General Hospital (GR)
  • Mario Negri Institute for Pharmacological Research (IT)
  • University College Cork (IE)
  • St. James's Hospital (IE)
  • Universität Ulm (DE)
  • University of Szeged (HU)
  • University of Limerick (IE)
  • University of Southern California (US)
  • Rijnstate Hospital (NL)
  • Maastricht University (NL)
  • University of Milan (IT)
  • Ospedale Policlinico San Martino (IT)
  • MultiMedica (IT)
  • Centro San Giovanni di Dio Fatebenefratelli (IT)
  • Aristotle University of Thessaloniki (GR)
  • Centre Hospitalier d'Arras (FR)
  • Centre Hospitalier de Lens (FR)
  • Centre Hospitalier de Béthune (FR)
  • Centre Hospitalier Universitaire Amiens-Picardie (FR)
  • Groupe Hospitalier de l'Institut Catholique de Lille (FR)
  • Roskamp Institute (US)
Corresponding author
Lawlor, Brian
Venue
PLOS Medicine
Published
2018-09-24
Volume
15
Issue
9
Pages
e1002660
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2891955176
Cited by
193
References
29
Citations by year
2026: 14 · 2025: 18 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 36 · 2020: 49 · 2019: 24 · 2018: 1
FWCI
18.91
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Cork Open Research Archive (University College Cork, Ireland) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by-nc-sa)
  • Figshare (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • University of Limerick Institutional Repository (University of Limerick) (submittedVersion, cc-by-nc-sa)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
  • National Institute for Health and Care Research (NF-SI-0616-10042)
  • European Commission (279093)
  • Agence Nationale de la Recherche (ANR-11-LABX-0009)
  • University College London Hospitals NHS Foundation Trust
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
nilvadipine, Alzheimer's disease, cognitive decline, dihydropyridine calcium channel blockers, disease-modifying therapy, Clinical Dementia Rating, NINCDS-ADRDA criteria, anti-inflammatory activity, amyloid, regional cerebral blood flow, adverse events
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Male, Middle Aged, Nifedipine, Treatment Outcome, Disease Progression, Nootropic Agents, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1002660
The paper
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., . . . for the NILVAD Study Group. (2018). Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.